ReviewGynecologic oncology reports2026

Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions.

Heena Arshad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.